Grounded in excellence and driven by innovation, our Industrial Operations and Product Supply (IOPS) team is responsible for the production of Regeneron products.

IOPS successfully manufactures a range of biopharmaceuticals for patients worldwide, including our approved therapeutic proteins and those involved in clinical studies.

Our operations follow strict adherence to current Good Manufacturing Practices (cGMP) and use cutting-edge analytical equipment, automated laboratory information management systems and electronic document management systems, all of which are supported by an extensive calibration, validation and preventive maintenance program. Our independent clean-room suites with ultra-modern clean utilities support both single-use and stainless steel cell culture bioreactors and large-scale chromatography systems designed to produce and purify our product candidates.

Supported by a highly skilled team of scientists, engineers, biotech production specialists and managers, our integrated teams bring an unsurpassed expertise in developing, operating, optimizing, validating and licensing the complex manufacturing processes required for production of biopharmaceuticals.

In 2019, our Rensselaer IOPS team was honored with the prestigious Shingo Prize, an annual award by the Shingo Institute recognizing companies who foster a culture of continuous improvement and manufacturing excellence.

We embrace our role — and the immense responsibility it carries — to produce the highest-quality medicines for patients as efficiently as possible.


TRUST in ourselves and each other to do the right thing

TEAMWORK across boundaries

TRANSPARENCY in our actions

DRIVE to continuously improve

RESPECT for site, self and others


IOPS has been manufacturing large-scale biologics since 2003, and has a long-term commitment to manufacturing growth and expanded operations across the globe.

As part of this commitment, we recently invested $200 million to expand operations in Rensselaer, New York. This facility has grown at a rapid pace since its acquisition in 1993. In 2013, we committed to a $300 million investment and 300 jobs for our overseas IOPS operation in Limerick, Ireland. In 2015, we dedicated an additional $350 million to add another 200 jobs by the end of 2017. This will make the new 400,000-square-foot, state-of-the-art facility the largest-scale bulk biologics Active Pharmaceutical Ingredient (API) production facility in Ireland, providing important new medicines to people with serious diseases worldwide. t

Explore our Irish operations

A little girl sits cross-legged, devouring a series of books about the earth. Captivated, she continues with the history of dinosaurs, one page at a time.

"I distinctly remember looking at descriptions of the earth's core thinking, 'How do you know this??' It was in that moment that I decided I had to know more."

Read Annie's story